Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Next Bristol/ImClone? “Standstill” Provisions Complicate Other Deals

Executive Summary

Roche and Bristol-Myers Squibb have everyone wondering who will be the next company to buy out its biotech partner
Advertisement

Related Content

Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?
Amylin, Lilly Partnership Tested By Lilly GLP-1 Project
Devilish Details: Icahn Looks To Boost Bristol/ImClone Offer
Bristol’s Proposed ImClone Acquisition May Beckon Potential Suitors
Bristol’s Proposed ImClone Acquisition May Beckon Potential Suitors
Roche’s High Stakes Gambit For Genentech
Change of Control: Why Getting it Right Matters Even More
Change of Control: Why Getting it Right Matters Even More
Lilly Brings Full Value Of Cialis In-House With Purchase Of Partner ICOS
Pfizer Does Not Stand Still: AmericanWarner Break-Up Provision Is Hurdle
Advertisement
UsernamePublicRestriction

Register

PS050080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel